Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting
08 nov. 2021 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array...
CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10
05 nov. 2021 15h25 HE
|
Eyenovia, Inc.
Eyenovia will release third quarter 2021 results on Wednesday, November 10, after the close. The prior version of this press release incorrectly stated that third quarter 2021 results would be...
Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11
04 nov. 2021 16h05 HE
|
Eyenovia, Inc.
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia
04 nov. 2021 08h00 HE
|
Eyenovia, Inc.
Vision-2 follows successful Vision-1 trial with expected top-line results in Q2 2022 Presbyopia represents a multi-billion-dollar market opportunity in the U.S. alone NEW YORK, Nov. 04, 2021 ...
Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA
25 oct. 2021 08h00 HE
|
Eyenovia, Inc.
Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review and reclassification of eye cups, eye droppers, and ophthalmic dispensers Company received Complete Response Letter...
Eyenovia Reports Second Quarter 2021 Financial Results
11 août 2021 16h05 HE
|
Eyenovia, Inc.
Announced positive topline data from its Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia Company on track to initiate second Phase 3 presbyopia trial, VISION-2, by...
Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11
04 août 2021 08h00 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array...
Eyenovia to Participate in Two Upcoming Investor Conferences
07 juil. 2021 16h01 HE
|
Eyenovia, Inc.
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array...
Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue
15 juin 2021 08h00 HE
|
Eyenovia, Inc.
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia
25 mai 2021 09h03 HE
|
Eyenovia, Inc.
Primary endpoint was achieved with well-tolerated micro-array print (MAP™) safety profile Upcoming key 12 month milestones include Mydcombi PDUFA; Vision 2 Phase 3 trial results and completion of...